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Discovery of disease-associated autoantibodies has transformed the clinical manage-
ment of a variety of neurological disorders. Detection of autoantibodies aids diagnosis 
and allows patient stratification resulting in treatment optimization. In the last years, 
a set of autoantibodies against proteins located at the node of Ranvier has been iden-
tified in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). These 
antibodies target neurofascin, contactin1, or contactin-associated protein 1, and we 
propose to name CIDP patients with these antibodies collectively as seropositive. They 
have unique clinical characteristics that differ from seronegative CIDP. Moreover, there is 
compelling evidence that autoantibodies are relevant for the pathogenesis. In this article, 
we review the current knowledge on the characteristics of autoantibodies against the 
node of Ranvier proteins and their clinical relevance in CIDP. We start with a descrip-
tion of the structure of the node of Ranvier followed by a summary of assays used to 
identify seropositive patients; and then, we describe clinical features and characteristics 
linked to seropositivity. We review knowledge on the role of these autoantibodies for the 
pathogenesis with relevance for the emerging concept of nodopathy/paranodopathy 
and summarize the treatment implications.
Keywords: autoantibody, seropositive, chronic inflammatory demyelinating polyneuropathy, node of Ranvier, 
paranode, neurofascin, contactin, contactin-associated protein 1
KeY POiNTS
 – Autoantibodies against neurofascin, contactin1, or contactin-associated protein 1 (Caspr) occur 
in approximately 10% of chronic inflammatory demyelinating polyneuropathy (CIDP) patients. 
We propose to call these collectively seropositive.
 – These autoantibodies target nodal and paranodal structures and typically have an IgG4 
isotype.
 – Unlike seronegative CIDP, there is no overt inflammation and demyelination in these patients.
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 – The pathology caused by these antibodies is named as nodo-
pathy/paranodopathy, which is characterized by dissection 
of myelin loops from axon at the paranode and subsequent 
axonal degeneration.
 – Seropositive CIDP patients have a specific clinical pheno-
type that is distinct from seronegative CIDP. They typically 
respond poorly to IVIg but may benefit from plasmapheresis 
and rituximab (RTX).
 – Thus, these autoantibodies have a diagnostic and prognostic 
value as a biomarker in CIDP.
 – Antibodies to neurofascin155 have also been reported in 
some patients with combined central nervous system (CNS) 
and peripheral nervous system (PNS) inflammation; how-
ever, the clinical relevance of this finding is not known at the 
moment.
iNTRODUCTiON
The molecular composition of the node of Ranvier has been 
characterized in the last 20  years (1–4), and autoantibodies 
that target these proteins, namely neurofascin, contactin1, and 
Caspr have been identified in chronic inflammatory demy-
elinating polyneuropathy (CIDP) in the past 6  years (5, 6). 
The presence of these autoantibodies has been shown consist-
ently in several studies and, although they are present in only 
about 10% of the patients with CIDP, their presence has been 
linked to different clinical and prognostic features compared to 
the patients who lack these antibodies. Therefore, we grouped 
the subset of patients with antibodies against neurofascin, 
contactin1, and Caspr under the term “seropositive CIDP.” 
While antibodies to gangliosides are frequently found in 
GBS, such autoantibodies are typically not found in CIDP (6). 
In this article, we
 (1) introduce the molecular components of the node of Ranvier
 (2) summarize the clinical phenotype of seropositive CIDP 
patients
 (3) review the treatment approaches
 (4) discuss the evidence for their pathogenic relevance and the 
concept of nodopathy
 (5) summarize the diagnostic methods to identify these sero-
positive patients.
STRUCTURe OF THe NODe OF RANvieR
Segregation of the voltage-gated sodium channels in axonal 
domains instead of diffusely floating on the membrane is a cri tical 
step during the evolution of vertebrates (7). This was followed 
by the myelination of the axons in higher vertebrates. These 
improvements provided organisms with a faster and more energy 
efficient way of conducting electrical signals throughout the 
longer and thicker axons, which is called saltatory propagation. 
Action potentials are generated in the axon initial segments 
(AIS) and regenerated in each node of Ranvier. AIS and nodes 
are also important for the adjustment of conduction velocity of 
individual axons to achieve synchronization at the network level 
(8). Thus, nodes of Ranvier are the critical components of the 
myelinated axons and they are not just uniform, passive sites 
where sodium channels are concentrated.
General Organization of the Axon
In unmyelinated axons, sodium channels are found diffusely 
throughout the axon. In myelinated axons, these channels are 
concentrated in the AIS and the nodes by means of their anchor-
ing motifs and the scaffold proteins (9). The scaffold of the axon 
is an orderly organized structure in the AIS and the nodes of 
Ranvier (10, 11). Circular actin bands are spaced every 190 nm 
perpendicular to the axolemma. Spectrins bind to actin circles 
and are located longitudinally just below the axonal membrane 
to provide an anchoring platform for the extracellular ion chan-
nels and cell adhesion proteins. Ankyrins mediate the binding 
of membrane-bound proteins with spectrins (12). The axonal 
domain located between the two nodes is called the internode. 
The length of the internode can reach 1 mm or more whereas the 
nodes have only a length of 1 µm (2).
The node of Ranvier is composed of three subdomains: node, 
paranode, and juxtaparanode (JXP) (Figure  1). Cell adhesion 
molecules, cytoskeletal elements, and extracellular matrix pro-
teins all contribute to the formation of these subdomains. In the 
literature, the term “node” is used for both the complex that is 
composed of all three subdomains and also to refer only to the 
nodal subdomain. Throughout this review, we use “the node of 
Ranvier” to refer to the whole complex and “node” to refer to the 
specific subdomain.
Node and AiS
Nodes are very active sites. Although they occupy only 0.1–0.3% 
of axonal surface, nodes contain 90% of the organelles that are 
found in the whole length of the axon and there is an active vesicle 
trafficking in the nodes (13). Axon thickness is diminished in the 
nodal and paranodal domains. Thus, nodes present a bottleneck 
for the anterograde and retrograde axonal transportation (14).
Neurofascin 186 (NF186) is the cell adhesion molecule that 
anchors voltage-gated sodium channels in the node and AIS 
(Figure 1). It is a transmembrane protein with six immunoglobu-
lin (Ig)-like domains, four fibronectin type III (Fn) domains, and 
one mucin domain (15). Its binding partner is ankyrin G inside 
the cell which in turn interacts with βIV-spectrin (16). In the 
PNS, NF186 interacts extracellularly with the soluble gliomedin 
and NrCAM that is located on the Schwann cell microvilli that 
fills the nodal space whereas in the CNS, NF186 interacts with 
extracellular matrix proteins.
The axonal initial segment is a specialized ~30 nm domain that 
is located next to the soma (12). The AIS contains a high number 
of ion channels and it is responsible for the initial formation of 
action potentials. Many of the structural components of AIS, 
including sodium and potassium channels, NF186, NrCAM, and 
their binding partners in the cytoskeleton, are identical to the 
node (17). Thus, autoantibodies against these elements would 
probably also affect the AIS.
Paranode
Paranodal junction (PNJ) is by far the largest intercellular 
junction known (18). Size of the PNJ depends on the number 
FiGURe 1 | Gross and molecular structure of the node of Ranvier in central nervous system (CNS) and peripheral nervous system (PNS). Cell adhesion molecules 
forms complex with other adhesion molecules, ion channels, and the cytoskeleton to form the nodal, paranodal, and juxtapranodal compartments. The main 
difference between the CNS and PNS nodes is the interaction partners of neurofascin 186 (NF186). The targets of the autoantibodies found in patients with 
seropositive chronic inflammatory demyelinating polyneuropathy are neurofascin 155, Cntn1, and contactin-associated protein 1, which altogether form a  
complex in the paranode (red rectangle); and NF186 that is located in the node (green rectangle) and also in the axon initial segment. Reprinted by  
permission from Springer Customer Service Centre GmbH: Springer Nature [COPYRIGHT] (5).
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of myelin lamella. An axon with 50 paranodal myelin loops has 
a 5  µm long paranode, much longer than the node (19). The 
largest axons may have up to 250–300 turns of myelin (20). PNJ 
is formed by the regularly spaced heterotrimeric complexes of 
contactin1 (CNTN1) and contactin-associated protein 1 (Caspr) 
on the axonal side, and neurofascin 155 (NF155) on the glial 
side (Figure 1) (21). These junctional complexes are also named 
as transverse bands because of their appearance under electron 
microscopy (22).
Neurofascin 155 is the glial isoform of NF186 which lacks its 
mucin domain and has an Fn3 domain instead of an Fn5 domain 
(23). It is alternatively spliced in the myelin-producing glia by 
an RNA-binding protein named Quaking (24). NF155 interacts 
with CNTN1 through its Ig domains (25). The cytoplasmic 
domain of the NF155 interacts with the ankyrin proteins (26). It 
is a glycoprotein like other cell-adhesion proteins and has eight 
glycosylation sites. Glycans of NF155 participate in the formation 
of complexes and are also important for autoantibody binding 
(27, 28). NF155 is palmitoylated and is located on the sulfatide-
rich lipid rafts (29, 30). Integrity of the PNJ is maintained not 
only through protein–protein interactions but also by virtue of 
the lipid rafts. Transgenic mice that are incapable of synthesizing 
sulfatides show a severe phenotype similar to neurofascin knock-
out mice (31).
Contactin1 is a glycosylphosphatidylinositol-anchored protein. 
It has six Ig domains and four Fn domains, similar to neurofascin 
and it forms a complex with Caspr on the axonal side (3). The 
interaction of these two proteins is critical for their trafficking to 
the paranode (32). Caspr binds to CNTN1 in the endoplasmic 
reticulum and together they bypass the conventional protein 
trafficking pathway that pass through Golgi and the complex is 
sent directly to the paranode. In this situation, CNTN1 carries a 
lower molecular weight mannose-rich glycan. This type of glycan 
side chain is critical for its binding with NF155. In the absence of 
Caspr, CNTN1 is sent to the node instead of the paranode, after 
modification with complex glycans in the Golgi apparatus (32). 
Caspr is a transmembrane glycoprotein which has laminin G-like 
domains, EGF-like cysteine-rich domains, a PGY motif, an amino-
terminal discoidin domain and a 4.1 binding domain (33, 34). 
Intracellularly, it is bound to protein 4.1B, and α2/β2 spectrins (35).
The main function of the PNJ is to block the passage of 
nodal currents into the internode. This is crucial for the salta-
tory conduction and its loss may result in conduction block 
(36). However, PNJs are not completely impermeable to all 
4Vural et al. Autoantibodies in CIDP
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molecules. Studies with different molecular weight dextrans 
showed that molecules as large as 160  Å (almost the size of 
an IgG) can pass through the PNJ (37). However, this does 
not happen through the 3  nm space between the axonal and 
glial membranes or the narrow channel between the junctional 
complexes. Instead, there is a triangle-shaped larger but much 
longer (100×) pathway between the adjacent myelin loops and 
axolemma. This long channel does not permit the diffusion of 
ions which are removed quickly from the nodal space but allows 
the slow diffusion of nutrients and larger molecules (37).
The PNJ is also directly involved in the formation and main-
tenance of the node of Ranvier. During formation, PNJ restricts 
nodal proteins to the node and thereafter it acts as a diffusion bar-
rier for the movement of voltage-gated ion channels found in the 
node and the JXP (4). Developmental knock-out mouse models 
of the PNJ complex proteins show a severe phenotype with severe 
ataxia, hind limb paresis, and death before the third postnatal 
week (36, 38, 39). Electrophysiological studies reveal dramatic 
reductions in the nerve conduction velocities. When NF155 was 
ablated during adulthood by knock-down of QKI, mice progres-
sively developed hind limb paralysis with visible thoracic kyphosis 
and numerous mice reached a clinical endpoint of accelerated 
breathing and immobility (24). Interestingly, these mice also 
displayed a characteristic shaking phenotype, reminiscent of 
the tremor seen in the CIDP patients with anti-NF155 antibodies.
Juxtaparanode
In the JXP, Caspr2 binds to contactin2 on the axonal side and 
interacts in trans with the glial contactin2 that is expressed on 
the myelinating glia (Figure 1). Caspr2 has a similar structure 
as Caspr, showing 45% identity at the amino acid level (40). 
However, it lacks the PGY motif, which plays an important role 
in trafficking of CNTN1 to the paranode, and has an additional 
PDZ binding domain. Intracellularly, Caspr2 binds to the pro-
tein 4.1 that plays an important role in the association of Caspr2 
with Kv1 channels and their clustering at the JXP (41). The AIS 
also contains several JXP components including Kv1 channels 
and Caspr2. Despite this molecular similarity, there are funda-
mental differences in the mechanisms that control ion channel 
distribution at the nodes of Ranvier and the AIS (4). At the 
JXP, clustering of Kv1 channels requires axon–glia interaction 
mediated by the Caspr2/Contactin2 adhesion complex, but not 
PSD proteins. In contrast, clustering of Kv1 channels at the AIS 
depends on the presence of PSD-93 but not on Caspr2. Besides, 
Caspr2 is found commonly also in inhibitory interneurons in the 
hippocampus, which explains the encephalopathy seen in the 
majority of patients with anti-Caspr2 autoantibodies (42). These 
autoantibodies also cause hyperexcitable peripheral nerves in 
many patients, however whether this is due to the dysfunction 
of the JXP or AIS is not exactly known at the moment. As the 
JXP is sequestered behind the paranode, autoantibodies may not 
be able to reach that site easily.
Differences Between the PNS  
and CNS Node
Although the overall structure and elements of the PNS and 
CNS are similar, some differences exist (Figure 1). In PNS, the 
nodal space is filled with the microvilli that originate from the 
Schwann cells. In PNS nodes, Schwann cells secrete gliomedin 
to the nodal space which form trimers. These trimers bind to 
NrCAM that is present on the microvillar membrane. This com-
plex creates a high avidity site for NF186-binding, promoting 
their aggregation to the node (43). In CNS, oligodendrocytes do 
not form microvilli and the nodal space is filled with extracel-
lular matrix proteins instead. Here, NF186 interacts with the 
extracellular matrix proteins including versican, brevican, and 
others (4). In terms of the paranode, the only difference identi-
fied so far is that NF155 interacts with ankyrin G in the CNS 
and ankyrin B in PNS (26). There are also differences in the tight 
junctions (Figure 1).
MeTHODS TO iDeNTiFY TARGeTS  
OF NODAL AUTOANTiBODieS
Neurofascin has been identified as a target of autoantibodies 
with a proteomic approach (44): Glycoproteins purified from 
human myelin by lentil-lectin affinity chromatography were 
separated by two-dimensional gel electrophoresis and blotted. 
The spots that were recognized by IgG of an MS patient were 
analyzed by mass-spectroscopy and this yielded neurofascin 
(44). Subsequently, human NF155 and NF186 were produced 
recombinantly for an enzyme-linked immunosorbent assay 
(ELISA), cell-based assays (CBA) with human NF155 and 
NF186 were established, and anti-NF155 Abs were found in a 
proportion of patients with CIDP by using these assays (27).
CNTN1 and Caspr were identified by using an approach 
that combines tissue-based assays (TBA), proteomics, and CBA 
(45, 46). Incubation of the patients’ sera with rodent-teased 
fibers showed colocalization of autoreactive antibodies with the 
nodal antigens in several patients. Subsequently, the target anti-
gen of the reactive antibodies in patients’ sera were identified 
by immunoprecipitation of the antigen–antibody complexes 
after incubating patients’ sera with neuronal culture cells, fol-
lowed by gel separation and analysis with mass spectrometry 
(45). Presence of NF155 and NF186 autoantibodies was verified 
independently by using a similar approach (28, 47).
MeTHODS TO DeTeCT AUTOANTiBODieS 
AGAiNST NODAL PROTeiNS iN PATieNT 
COHORTS
CIDP-related autoantibodies so far identified react with cell 
surface proteins that are found in their native three or four 
dimensional form. TBA provide an efficient method to screen 
the presence of such antibodies. In this assay, binding of anti-
bodies in patient sera to rodent brain, spinal cord, or peripheral 
nerve tissue sections is determined. When reactivity is detected, 
specific tests are necessary to identify the target antigen of these 
autoantibodies (Table 1).
In earlier studies, peptide-based ELISA and western-blotting 
were used for that purpose, but they were found to have a low 
specificity. This is intuitive as these assays utilize peptide frag-
ments or denatured proteins instead of native proteins. Recent 
TABLe 1 | Methodologies and disease groups of the previous studies testing antibodies against nodal proteins in chronic inflammatory demyelinating polyneuropathy 
(CIDP) and peripheral neuropathies.
Assay method
Study (year) eLiSA species of the 
antigen
CBA species  
of the antigen
Rodent 
nerve iF
Rodent  
brain/spinal 
cord iHC
Targets of  
antibodies  
tested
Patient Groups Reference
Prüss et al. (2011) Rat – – – Neurofascin, CNTN2 GBS (48)
Ng et al. (2012) Human Human – + NF155, NF186 CIDP, GBS (27)
Querol et al. (2013) – Human + – CNTN1 CIDP, GBS (45)
Kawamura et al. (2013) Rat Human + + NF155 CCDP (49)
Querol et al. (2014) Human Human + + NF155, NF186 CIDP, GBS (50)
Notturno et al. (2014) Rat peptide Human + – NF186, gliomedin MMN (51)
Ogata et al. (2015) – Human + – NF155, NF186 CIDP, GBS, MS (52)
Vural et al. (2015) Human – – – NF155 CCPD (53)
Doppler et al. (2015a) Human Rat + + CNTN1 CIDP, GBS (54)
Doppler et al. (2015b) Human Human & Rat + – NF155, NF186, CNTN1 MMN (55)
Miura et al. (2015) Human Human + + CNTN1 CIDP, GBS, MS (56)
Devaux et al. (2016) Human Human + + NF155, NF186 CIDP, GBS, MS (28)
Cortese et al. (2016) Human Human + – NF155 CCPD, CIDP, MS (57)
Doppler et al. (2016) – Human + + Caspr CIDP, GBS (46)
Kadoya et al. (2016) Human Human + – NF155 CIDP, GBS, MS (58)
Mathey et al. (2017) Human Human + + NF155, NF186, CNTN1, 
gliomedin
CIDP, MMN (59)
Delmont et al. (2017) Human Human + + NF186, NF140, gliomedin,  
NF155, CNTN1, Caspr
CIDP, GBS, MS (47)
Querol et al. (2017) Human Human + – NF155, CNTN1, NrCAM, 
gliomedin, CNTN1/Caspr & 
CNTN2/Caspr2 complexes, 
NavB1 and NavB2,  
gangliosides, MPZ, PMP2
CIDP (6)
Koike et al. (2017)a Human Human Human – NF155, CNTN1 CIDP (60)
Garg et al. (2017) Human – – – NF155 CIDP (61)
Burnor et al. (2018) – Mouse & Rat – – NF155, NF186, NF140 CIDP, GBS, genetic 
neuropathy, idiopathic 
neuropathy
(62)
aResults of the anti-NF155 antibody testing were reported in Ref. (58).
ELISA, enzyme-linked immunosorbent assay; CBA, cell-based assay; IF, immunofluorescence; IHC, immunohistochemistry; CNTN2, contactin2; GBS, Guillain-Barre Syndrome; 
NF155, neurofascin 155; NF186, neurofascin 186; CIDP, chronic inflammatory demyelinating polyneuropathy; CNTN1, contactin1; CCPD, combined central and peripheral 
demyelination; MMN, multifocal motor neuronopathy; MS, multiple sclerosis; Caspr, contactin-associated protein 1; NF140, neurofascin 140; NrCAM, neuronal cell adhesion 
molecule; MPZ, myelin protein zero; PMP2, peripheral myelin protein 2.
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development of CBA provided an efficient method to detect 
autoantibodies against epitopes that are found in the native 
form of proteins (Table  1). In CBA, mammalian culture cells 
transfected with the specific target protein are incubated with 
patient serum. Another sensitive method is ELISA (Table 1). The 
expression system used to synthesize target protein for ELISA is 
also important as proteins expressed by non-human cells may 
have different post-translational modifications, which in turn 
may affect the antibody–antigen interaction. In a previous study, 
only a few serum samples from CIDP patients showed reactivity 
to NF155 and NF186 expressed in HEK293-EBNA cells, whereas 
virtually all donors showed some response against ratNF155 
derived from NS0 murine myeloma cells (27).
The utility of CBA or ELISA to detect autoantibodies differs 
between different antigens. It may be difficult to interpret the 
results in some patients despite the usage of a specific assay if the 
result is near the cut-off value. Test results should be evaluated 
together with the clinical picture of the patient and repeated 
testing of serum taken during different phases of the disease may 
provide valuable information.
CLiNiCAL iMPLiCATiONS OF ANTiBODieS 
AGAiNST NODAL ANTiGeNS
Nodal Autoantibodies
Neurofascin 186 and gliomedin have been the usual suspects 
since the node of Ranvier antigens came into focus as targets 
of autoantibodies in GBS and CIDP (63). However, several 
consecutive studies that used native human gliomedin could 
not identify its presence in these disorders, and NF186 could 
only be detected in two studies indicating their rarity (27, 47) 
(Table 2).
In a large European cohort of 246 CIDP patients, 5/246 patients 
had anti-NF186 antibodies (47). These antibodies had a similar 
reactivity to NF140, which is predominantly expressed at early 
developmental stages and also strongly expressed in lesions of MS 
patients (64), and NF155. Sera from these patients stained both the 
nodes and AIS at the same time (47). Compatible with this find-
ing, the patients had a more severe and subacute onset compared 
to antibody-negative CIDP patients. Sensory ataxia was com-
mon and average age of onset was older. Electrophysiologically, 
TABLe 2 | Studies that tested autoantibodies against neurofascin 186 (NF186) and gliomedin by using native human proteins.
NF186 Gliomedin
Study (year) CiDP GBS MMN CiDP GBS MMN isotype Reference
Ng et al. (2012) 0/119 2/115 – – – – IgG1, IgG3 (27)
Querol et al. (2014) 0/53 0/51 0/22 – – – – (50)
Ogata et al. (2015) 0/50 0/26 – – – – – (52)
Doppler et al. (2015b) – – 0/33a – – – – (55)
Devaux et al. (2016) 0/533 0/200 – – – – – (28)
Mathey et al. (2017) 0/44 – 0/15a 0/44 – 0/15 – (59)
Delmont et al. (2017) 5/246 0/26 – 0/246 0/26 – IgG4, IgG3 (47)
Burnor et al. (2018) 1/40b 0/14 – – – – IgG4 (62)
Total 6/1046 2/432 0/70 0/290 0/26 0/15
aNF155 also negative.
bSerum from this patient was reactive to NF186, NF155, and NF140.
NF186, neurofascin 186; CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barre Syndrome; MMN, multifocal motor neuronopathy.
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there was conduction block that reversed after immunotherapy. 
Importantly, intravenous immunoglobulin (IVIG) response was 
better (47) compared to anti-NF155 positive patients (28, 50, 
52, 58). In a separate study, a 50-year-old man with a very severe 
form of CIDP, who almost progressed into a locked-in state, had 
antibodies that recognize all three neurofascin isoforms, with 
higher anti-NF186 titers compared to anti-NF155 (62).
Antibodies against NF186 have also been analyzed in MMN 
in several studies; however, none of the patients was found to 
be positive by testing against native human proteins so far 
(50, 55, 59) (Table 2). In only one study, 60% of the patients with 
MMN had antibodies against anti-NF186 and anti-gliomedin; 
however, this study is methodologically different from others 
as rat peptides were used for detection of autoantibodies (51).
Paranodal Autoantibodies
Anti-NF155
Chronic Inflammatory Demyelinating Polyneuropathy
Anti-NF155 antibodies have been consistently reported in a 
fraction of patients with CIDP (Table 3) and have been strongly 
associated with HLA-DRB1*15 (65). The reported frequency is 
between 4 and 18% and it was 7% in a large cohort of 533 patients 
(27, 28, 50, 52, 58, 59, 61). In several studies, a specific clinical 
phenotype that differs from the antibody negative CIDP has been 
described (Table 3). This includes a younger age of onset around 
20–30 years instead of 50–60, a subacute and more severe onset, 
disabling tremor, sensory and cerebellar ataxia, distal dominant 
weakness, and poor response to IVIG (28, 50, 52, 58). Laboratory 
and electrophysiological findings that were associated with 
anti-NF155 antibodies were higher levels of cerebrospinal fluid 
protein and marked prolongation of distal and F-wave latencies 
(52, 58). Additionally, gadolinium enhancement and enlargement 
in the spinal roots and plexuses have been described in patients 
undergoing magnetic resonance (MR) neurography (52). Diffuse 
peripheral nerve enlargement and cranial nerve hypertrophy 
have also been reported (61, 66).
Although early studies reported that anti-NF antibodies are 
associated with GBS, succeeding studies performed with native 
human antigens produced in mammalian cell lines showed that 
these antibodies are only very rarely (<1%) positive in patients 
with GBS (63, 48).
Combined Central and Peripheral Demyelination (CCPD)
Anti-NF155 antibodies have also been described in CCPD 
patients from Japan in 5/7 CCPD patients (49). The researchers 
used ELISA with native rat NF155 as the initial screening method 
and confirmed the results with a cell based assay that expressed 
human NF155. Most of the anti-NF155 positive CCPD patients 
in this study had typical findings of both MS and CIDP. However, 
oligoclonal bands were negative in 4/5 patients and response to 
corticosteroids was only partially effective in most patients. In an 
additional study again from Japan, anti-NF155 antibodies were 
reported in 5/11 of the CCPD patients tested, but information 
regarding methodology of testing and clinical characteristics of 
these patients were not present in this article (67). Another study 
investigated the presence of CNS demyelination in CIDP patients 
that are positive for anti-NF155 antibodies and found that 3/38 
of these patients had additional signs of central demyelination, 
compared to none in antibody-negative CIDP patients (28). 
Signs of central demyelination in these patients were much less 
prominent compared to the patients reported by Kawamura et al. 
(49). In this study, sera from anti-NF155 antibody positive CIDP 
patients were also incubated with rat brain tissues and reactivity 
were positive regardless of the presence or absence of central 
demyelination in patients.
Two studies tested CCPD patients of non-Japanese origin for 
the presence of anti-NF155 antibodies and none of the patients 
were positive (Table  3) (53, 57). In the first study (53), four 
patients who fulfilled the criteria for both MS and CIDP with a 
positive response to plasmapheresis were tested by ELISA using 
human NF155 and NF186. Interestingly, three of these patients 
had clinical characteristics of anti-NF155 antibody-positive 
CIDP including young age of onset, a subacute and severe onset 
of CIDP, lack of response to IVIG, diffusely enlarged, gadolinium 
enhancing nerve roots, and high CSF protein levels. One patient 
had also disabling tremor. These findings suggest that other 
antibodies may also be involved in CCPD patients (53). In the 
second study, patient cohort included 16 patients, three of whom 
presented as young-onset MS plus CIDP syndrome similar 
to the Japanese cohort, but they were seronegative. Similarly, 
13 patients who presented as older-onset myeloneuroradicu-
litis with or without encephalopathy in the same cohort also 
were seronegative for anti-NF155 antibodies (57). Recently, an 
TABLe 3 | Studies that tested autoantibodies against neurofascin 155 (NF155) by using native human proteins.
Diagnosis
Study (year) CiDP GBS CCPD MS isotype Clinical characteristics Reference
Ng et al. (2012) 6/119 2/115 – – IgG4 (CIDP) 
IgG1(GBS)
Positive response to plasma exchange (27)
Kawamura  
et al. (2013)
0/16 0/20 5/7 0/20 Not done Peripheral nerve demyelination is  
indistinguishable from CIDP, CNS  
involvement is mostly typical for MS, CSF  
OCB are negative mostly, response to 
corticosteroids is limited
(49)
Querol et al. (2014) 2/53 and 2/8a 0/51 – – IgG4 Severe phenotype, poor response  
to IVIG, and disabling tremor
(50)
Ogata et al. (2015) 9/50 1/26 – 0/32 IgG4 (CIDP) 
IgG1(GBS)
Younger onset age, tremor, extremely high  
CSF protein levels, symmetric spinal root  
and plexus hypertrophy, and marked  
prolongation of distal and F-wave latencies
(52)
Vural et al. (2015) – – 0/5 – – – (53)
Devaux et al. (2016) 38/533 0/200 – 0/100 IgG4 Younger age at onset, subacute onset,  
sensory and cerebellar ataxia, tremor,  
CNS demyelination, poor response to IVIG
(28)
Cortese et al. (2016) 1/26 – 0/16 0/15 IgG4 Distally predominant weakness, ataxia,  
tremor, and IVIG resistance
(57)
Kadoya et al. (2016) 15/191 0/57 – 0/16 IgG4 Younger CIDP onset, distal dominant  
phenotype, tremor, and sensory ataxia,  
higher levels of CSF protein, poor response 
to IVIG, mRS scores at diagnosis was higher, 
patients underwent PE more frequently
(58)
Mathey et al. (2017) 3/44 – – – IgG4 – (59)
Delmont et al. (2017) 9/246 0/26 – 0/52 – – (47)
Garg et al. (2017) 3/55 – – – – Sensory ataxia, tremor (in 1/3), diffuse  
nerve enlargement, IVIG resistance
(61)
Burnor et al. (2018) 4/40 1/14 – – IgG4 (CIDP) IgM 
(GBS)
High CSF protein; severe, progressive  
CIDP; poor response to IVIG
(62)
Total 90/1403 4/496 5/28 0/235
aAmong IVIG resistant CIDP.
CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barre Syndrome; CCPD, combined central and peripheral demyelination; MS, multiple sclerosis; CNS, 
central nervous system; CSF, cerebrospinal fluid; OCB, oligoclonal bands; IVIG, intravenous immunoglobulin; mRS, modified Rankin score; PE, plasma exchange.
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NF-155- and NF-186-specific T cell response without Abs to NF 
was described in a patient developing pontocerebellar demyelina-
tion after 10 years of CIDP (68).
Possible reasons for the different abundance of anti-NF155 in 
CCPD in the published studies include differences in ethnicity 
[Caucasian (53, 57) vs Japanese (49, 67)] and also the heterogene-
ity of CCPD.
Anti-CNTN1
Contactin1, the binding partner of NF155 on the neuronal side, 
is another target of autoantibodies in CIDP. Anti-CNTN1 anti-
bodies were first described by Querol et al. (45) and then further 
characterized by subsequent studies (47, 54, 56, 59, 60) (Table 4). 
Frequency of these antibodies in CIDP patients is between 3 and 
8%. Anti-CNTN1 antibodies are associated with specific clinical 
features including a more advanced age of onset compared to 
antibody-negative CIDP, an aggressive and GBS-like subacute 
onset of weakness, a very high ratio of sensory ataxia, early 
axonal involvement and poor response to IVIG. Tremor may 
also be more common in these patients than antibody-negative 
patients, despite being less frequent compared to anti-NF155 
positive patients. Corticosteroids were effective. These antibodies 
were also tested in patients with GBS and MMN, but none were 
positive (Table 4).
Anti-Caspr
Initially, anti-Caspr antibodies have been found in one patient 
with CIDP and another patient with GBS, both of whom had 
very severe pain that necessitated treatment with high dose 
pregabalin and opioids as a distinguishing feature (Table  5) 
(46). Sera from these patients reacted with small TRPV1 posi-
tive neurons in the dorsal root ganglia, potentially explaining 
the cause of severe pain. Apart from this finding, clinical 
features were quite similar to the patients with antibodies 
against the other paranodal antigens. The patient diagnosed 
with CIDP was young (30 years old) and onset of disease was 
TABLe 5 | Studies that tested autoantibodies against contactin-associated protein 1.
Diagnosis
Study, year CiDP GBS MS isotype Clinical characteristics
Doppler et al. (2016) 1/35 1/22 – IgG4 (CIDP)  
and IgG3 (GBS)
Severe pain; subacute, severe, motor dominant  
onset, reversible conduction block, unresponsive  
to IVIG, and corticosteroids
Delmont et al. (2017) 2/246 0/26 0/52 – –
Total 3/281 1/48 0/52
CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barre Syndrome; MS, multiple sclerosis; IVIG, intravenous immunoglobulin.
TABLe 4 | Studies that tested autoantibodies against CNTN1 by using native human proteins.
Diagnosis
Study (year) CiDP GBS MMN isotype Clinical characteristics Reference
Querol et al. (2013) 3/46 0/48 – IgG4 Advanced age, predominantly motor involvement,  
aggressive symptom onset, early axonal involvement,  
poor response to IVIG
(45)
Miura et al. (2015) 13/533 0/200a – IgG4 Subacute onset of symptoms, sensory ataxia, poor  
response to IVIG, good response to corticosteroids
(56)
Doppler et al. (2015a) 4/53 0/51 – IgG4 & IgG3 Acute onset of disease, severe motor symptoms,  
tremor, partial response to IVIG
(54)
Doppler et al. (2015b) – – 0/33 – – (55)
Mathey et al. (2017) 3/44 – 0/15 IgG4 – (59)
Delmont et al. (2017) 2/246 0/26 – – – (47)
Koike et al. (2017) 1/131 – – IgG4 – (60)
Total 26/807 0/325 0/48
a5 pts with GBS had IgG2 abs but did not stain-teased fibers.
CIDP, chronic inflammatory demyelinating polyneuropathy; GBS, Guillain-Barre Syndrome; MMN, multifocal motor neuronopathy; IVIG, intravenous immunoglobulin.
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subacute, severe, and motor dominant. He was unresponsive 
to IVIG and methylprednisolone and required walking-aid in 
a few months. Remarkably, pain resolved quickly after effective 
immunotherapy in both patients. In the patient with CIDP, 
response to RTX was very good and the patient could walk 
independently after 20 months of therapy. Two more patients 
have been reported recently, validating the rare presence of 
these autoantibodies in CIDP (47).
Summary of the Clinical Relevance of 
Antibodies Against the Node of Ranvier
The data reviewed in this paper show that CIDP is associated with 
antibodies mainly against paranodal proteins (NF155, CNTN1, 
and rarely Caspr) and to a lesser extent NF186 in around 10% of 
patients. These patients designated seropositive CIDP have dif-
ferent clinical features compared to seronegative CIDP (28, 59) 
(Tables  2–5). While there is now consensus that a proportion 
of patients with CIDP has autoantibodies against NF, Caspr, or 
CNTN1, the presence of autoantibodies against the myelin pro-
teins such P2, P0, PMP-22, and connexin has been described in 
some reports, but this was not confirmed by others (69).
Anti-NF155 antibodies may also be associated with CCPD, 
but this topic requires further studies. Despite early reports, 
anti-gliomedin antibodies directed against the conformational 
epitopes could not be shown in patients with inflammatory 
demyelinating disorders, yet. In GBS, antibodies against NF155, 
NF186, and Caspr may be detected only very rarely (<1%) 
suggesting their limited usage as a biomarker in this disorder 
(Tables 2, 3 and 5). Instead, the detection of these antibodies in 
GBS patients may be a marker for the development of acute-onset 
CIDP. In MMN, autoantibodies against NF186, Gliomedin, and 
CNTN1 are typically not found (Tables 2–5).
ig iSOTYPeS
The dominant isotype of the autoantibodies in seropositive 
CIDP patients is IgG4 (Tables 2–5). All reported patients (90/90) 
with anti-NF155, 22/24 of anti-CNTN1 positive patients, one 
patient with anti-Caspr antibody, and 5/6 of anti-NF186 posi-
tive patients had IgG4. Only two patients with anti-CNTN1 and 
one patient with anti-NF186 antibodies had IgG3 as the dominant 
subclass (47, 54). Anti-CNTN1 antibodies were of IgG2 isotype 
in three patients; however, these sera did not react with murine 
nerve fibers and not considered as positive or pathogenic. Of 
note, complement-fixing IgG1 (27, 52, 56, 59, 62), IgG2 (47, 50, 
52, 54, 56, 62, 70), and IgG3 subtype antibodies (71) were also 
detected in the sera of some CIDP patients concomitant with but 
at lower levels than IgG4.
BOx 1 | Features of IgG4 antibodies.
A sequential switching toward IgG3-IgG1-IgG2-IgG4 occurs with increasing 
levels of somatic hypermutations during a germinal center response.
Continuously undergo half-antibody exchange (functionally hetero-bispecific).
Cannot effectively cross-link target antigens.
Unable to bind C1q, so cannot activate complement.
Show little FcR binding.
Titers drop dramatically in response to RTX therapy.
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IgG4 has several characteristic features different from the 
other IgG subtypes (Box  1) (72, 73). IgG4 represents approxi-
mately 5% of the total IgG pool. Repeated or long-term exposure 
to non-infectious antigens, for instance allergens, leads to IgG4 
predominance. These antibodies continuously undergo half-
antibody exchange and are thus functionally hetero-bispecific 
which implies that only one arm of the antibody binds to its 
cognate antigen and thus cannot effectively cross-link target 
antigens. IgG4 cannot activate complement because it is unable 
to bind the first complement cascade component C1q and also 
show little FcR binding. These two mechanisms are critical for 
the effector function of the IgG1-3 antibodies. Another clinically 
important feature of IgG4 antibodies is that their titers drop dra-
matically in response to RTX therapy, unlike the IgG1 antibodies 
(74, 75) indicating that IgG4 producing cells do not persist as 
long-lived plasma cells in contrast to many IgG1 producing cells. 
Accordingly, RTX has been proven useful in anti-Musk (IgG4) 
myasthenia gravis in a recent clinical trial (76), and it seems also 
to be effective in patients with CIDP and autoantibodies of the 
IgG4 isotype (see Treatment Implications).
The coexistence of IgG3 with IgG4 may contribute to the 
pathophysiology of anti-contactin-1 associated neuropathy by 
causing complement deposition, and this may be related to the 
IVIG-response of the patient (71). Further studies are necessary 
to understand the clinical importance of coexisting IgG subtypes.
ePiTOPe MAPPiNG
Fn3-Fn4 region of the NF155 protein is unique to this neuro-
fascin isoform and not found in the NF186 and NF140 isoforms. 
This specific region was found to be the main epitope based on 
the sera of two patients with anti-NF155 antibodies (27). This 
finding was confirmed in a larger study by using the FN1-4 region 
for epitope mapping. The authors found that 30/38 (79%) of the 
patients required Fn1-4 region to bind to the protein (28). Fn1-2 
domains of NF186 interact with gliomedin and sodium channels, 
but the function of the Fn domains is not known for NF155 (77).
Neurofascin 155, NF186 and NF140 proteins are isoforms of 
the same protein. Whereas antibodies against NF155 recognize 
the Fn3-Fn4 domain that is unique to NF155, NF186/140 auto-
antibodies recognize the common Ig region (47). Indeed, sera 
from patients with NF186/140 antibodies reacted also to NF155 
(47, 62). The authors concluded that these antibodies mainly react 
to NF186/140 in vivo, by showing that the sera of these patients 
mainly stain the nodes and AIS of in teased fiber preparations 
(47). It can be speculated that this is due to the sequestration 
of this domain when NF155 interacts with CNTN1 to form a 
complex. As expected, patients with high anti-NF155 titers found 
in this study did not react against anti-NF186/140 proteins.
For anti-CNTN1 antibodies, the main epitope region is the 
Ig domain which also plays a role in its binding to NF155. To 
be more specific, 8/10 sera bound to the Ig5-6 domain (56). 
Furthermore, glycosylation was found to be important for anti-
NF155 antibodies to bind their targets (27), whereas anti-CNTN1 
antibodies could bind both the glycosylated and deglycosylated 
proteins equally (56). Intriguingly, in one patient, reactivity to 
CNTN1 could only be detected when it was in complex with 
Caspr (45).
The main epitope region for anti-Caspr antibodies is not 
known yet. Autoantibodies against its homologous protein, 
Caspr2, bind mainly to the discoidin domain and do not require 
native protein structure (as they are still reactive when WB is used 
to test) or glycosylation (78).
PATHOGeNiCiTY OF THe NODAL 
AUTOANTiBODieS
A combination of humoral and cellular immunity is commonly 
assumed to contribute synergistically to the pathogenesis in 
CIDP (69). T cells break the blood-nerve barrier allowing access 
of serum proteins like antibodies to the nerve environment 
(69). The paranodal localization of NF155 suggests that disrup-
tion of the paranodal structure may be necessary before auto-
antibodies are able to bind in vivo (68, 69). Recently, neurofascin 
and compact myelin antigen-specific T cell response pattern have 
been analyzed in CIDP subtypes (79).
In Lewis rats immunized against peripheral myelin, early loss 
of NF186 and gliomedin and redistribution of potassium chan-
nels were found to precede demyelination, and this finding was 
associated with detection of antibodies against neurofascin and 
gliomedin (80). Transfer of pan-neurofascin mAbs (A12/18.1 
mouse IgG2a and A4/4.3 mouse IgM) to Lewis rats in the begin-
ning of clinical EAN caused enhancement and prolongation of 
the disease (27). In this model, the antibodies to NF enhanced a 
T cell-mediated pathology. In another study, nerve conduction 
studies showed that intraneural injection of A12/18.1 mAbs, 
induces reversible conduction block (81).
Recently, direct evidence on the pathogenesis patient-derived 
antibodies was obtained. First, it was shown that IgGs from 
patients with anti-CNTN1 antibodies prevent aggregation of 
Caspr/contactin1 cotransfected cells with the NF155 expressing 
cells in a cell aggregation assay (70). In the same study, patient 
IgGs caused nodal elongation and paranodal shortening in dorsal 
root ganglion/Schwann cell cultures. In another study (54), myeli-
nated fibers of the skin from patients with anti-CNTN1 antibod-
ies were analyzed by immunofluorescence. There was elongation 
of the nodes and loss of paranodal Caspr and/or neurofascin 
immunoreactivity providing the first morphological evidence 
of nodal/paranodal disturbance in seropositive CIDP patients 
(54). Importantly, axonal but not demyelinating neuropathy 
was detected in the sural nerves of these patients. Accordingly, 
demyelinating features were not prominent in the sural nerves 
of two patients in another study (52). Similarly, in a patient with 
anti-Caspr antibody positive CIDP, pathological diagnosis of the 
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sural biopsy was axonal neuropathy and again there was severe 
dispersion of Caspr, neurofascin, and sodium channels in teased 
nerve fibers and dermal myelinated fibers (46). In these stud-
ies, T cell and macrophage infiltration were not reported to be 
prominent in the tissues examined.
IgG1 and IgG4 antibodies from CIDP patients with anti-
CNTN1 IgG were purified and either applied by intraneural 
injections or incubated with isolated murine sciatic nerves 
(82). They found that IgG4 antibodies can pass through the 
PNJ slowly but progressively. In contrast, IgG1 and anti-Caspr2 
IgG4 did not pass through the paranodal barrier. In the same 
study, passive transfer of IgG4 antibodies from patients with 
anti-CNTN1 IgG to Lewis rats after immunization with P2 
peptide caused progressive clinical deterioration and ataxia 
and the pathological examination revealed selective loss of 
paranodal compartmentalization without any signs of axonal 
or demyelinating neuropathy. Finally, two studies investigated 
the sural nerves of anti-NF155 antibody positive CIDP patients 
ultrastructurally. In the first study, selective loss of transverse 
bands at the PNJ causing widening of the periaxonal space and 
infiltration of the Schwann cell processes were reported (83). 
The second study compared the histological and ultrastruc-
tural features of the sural nerves from 10 seropositive patients 
(9 with anti-NF155, 1 with anti-CNTN1) to 13 seronegative 
CIDP patients (60). Again, there was no obvious macrophage or 
cellular infiltration and demyelination in seropositive patients at 
the time of biopsy contrary to the seronegative group. There was 
a loss of transverse bands, detachment of the terminal myelin 
loops and widening of the periaxonal gap in around half of 
the paranodes examined. Teased-fiber examination showed a 
prominent axonal degeneration compared to antibody-negative 
CIDP patients and controls. There was a positive correlation 
between axo-glial detachment and axonal degeneration. Two 
recent studies showed that the level of anti-NF155 IgGs in serum 
is also related to functional parameters of the patients (84, 85). 
Electrophysiological measurements, including F-wave latency, 
distal latency motor conduction velocity, of three patients with 
CIDP and anti-NF155 antibodies changed in parallel with the 
serum autoantibody levels and also with grip strength test (84). 
Interestingly, in another patient, restoration of compound mus-
cle action potential of the affected nerves, namely median and 
ulnar nerves, was observed after 18 years of disease onset and 
14 years under steroid therapy (85). This observation suggests 
that a reversible conduction block similar to that in the acute 
motor axonal neuropathy (AMAN) form of GBS is possible also 
in seropositive CIDP.
How do the antibodies pass through the blood-nerve bar-
rier? This barrier is permeable at the dorsal root ganglia, nerve 
roots, and end plate regions and antibodies may pass through 
these sites to travel to the nodes (5, 86). Of note, although sural 
nerve biopsies did not show any signs of prominent inflam-
mation in the distal nerve, MR neurography studies showed 
prominent gadolinium enhancement and enlargement in nerve 
roots and CSF protein levels were found to be very high in sero-
positive CIDP patients in most studies, which may indicate the 
presence of inflammation and BNB disruption in the proximal 
nerves (52, 86).
Additional mechanisms yet unidentified are probably also 
in action. The contribution of coexisting complement-fixating 
IgG subtypes to pathogenesis was tested by in  vitro studies. 
Binding of anti-CNTN1 auto-antibodies of three patients who 
had additionally IgG2 and IgG3 induced complement deposition 
and activation as measured by cell binding and ELISA-based 
assays (71). Whether this also happens in  vivo is not known. 
In one study, sural nerve biopsy specimens from two patients 
(one positive for anti-NF155, the other for anti-CNTN1) were 
examined for complement deposition and both were negative 
(60). Furthermore, NF155 antibodies and the extracellular 
domain of NF155 inhibit myelination in myelinating cocultures 
(21). Thus, it is also likely that presence of these antibodies have 
a negative effect on remyelination after injury.
THe CONCePT OF NODOPATHY
Peripheral neuropathies are traditionally classified as either 
demyelinating or axonal. However, electrophysiological studies 
in patients with AMAN, a subtype of GBS, showed that these 
patients carry features that cannot be explained by any of these 
two categories (87). AMAN is associated with IgGs against GM1 
gangliosides which were shown to disrupt the nodal structure 
without any overt demyelination in rabbits (88). These comple-
mentary clinical and preclinical findings led to the concept of 
nodopathy, which refers to a node/paranode based pathology, 
without any overt classical axonal or demyelinating features. 
Recently, this concept was widened to include neuropathies 
with different etiologies and autoantibodies that target the 
nodal and paranodal proteins (89). The disorders described in 
this review have many common clinical and laboratory features 
with the nodopathies, so they should not be regarded as demy-
elinating disorders, although they are clinically grouped under 
the chronic inflammatory “demyelinating” neuropathies at the 
moment. This point is worth to mention as it has treatment 
implications.
Seropositive CIDP differs from seronegative CIDP in terms 
of disease mechanism. In seronegative CIDP, the proximal nerve 
involvement is prominent and pathology shows segmental 
demyelination and other demyelinating features, T-cell and mac-
rophage infiltration and a milder, secondary axonal degeneration 
(69). On the other side, in seropositive CIDP, there is absence 
of macrophage-mediated demyelination, inflammatory cell infil-
tration, and axonal pathology is more severe (52, 54, 60). The 
mechanism of axonal pathology in these disorders is not fully 
understood yet but is thought to result from the increased ion flux 
secondary to redistribution of sodium channels and disturbance 
of the metabolic, structural, and trophic support that comes from 
the glia (90).
This pathophysiological discrepancy is also reflected by 
the clinical phenotype of the patients (Table  6). Because of 
these differences, treatment and follow-up strategies should be 
tailored according to the autoantibody status of the patients, an 
implication which is supported by the studies reviewed in this 
paper. Depending on this recent shift in the CIDP paradigm, 
Kuwabara et al. stated that it may be better to term CIDP as 
a syndrome rather than a single homogenous disease (91). 
TABLe 6 | Summary of differences in the clinical phenotype between seropositive and seronegative chronic inflammatory demyelinating polyneuropathy (CIDP) patients.
Seropositive CiDP Seronegative CiDP
Neurofascin 155 Contactin1 Caspra Neurofascin 186
Age of onset, years 20–30 50–60 30 50–60 50–60
Subacute onset ++ ++ ++++ ++++ +
Tremor ++ + – – +
Sensory ataxia +++ ++++ – ++++ +
Severe pain – – ++++ – Very rare
Central nervous system demyelination + – – – Very rare
Intravenous immunoglobulin unresponsiveness ++++ +++ ++++ ++ ++
aBased on one CIDP case. Data presented in this table is mainly derived from Ref. (28, 46, 47). Frequencies were determined as follows: ++++ means between 80–100%;  
+++ means 50–79%; ++ means 20–49%; + means 5–19%; 5% > is very rare.
TABLe 7 | Treatment response in seropositive chronic inflammatory demyelinating polyneuropathy patients.
Study Steroid response iviG response Pe response RTx response Others Reference
Anti-NF155
Querol et al. (2014) 1/4 (partial) 0/4 2/2 None (n = 1) CY none (n = 1) (50)
Querol et al. (2015) – – – Good (n = 1) Partial (n = 1) – (75)
Ogata et al. (2015) 5/8 4/13 4/6 – – (52)
Kadoya et al. (2016) Favorable 3/11 Favorable – – (58)
Devaux et al. (2016) 15/29 5/25 Not good – – (28)
Garg et al. (2017) 2/3 1/3 – Good (n = 1) MMF good (n = 1) (61)
Burnor et al. (2018) 1/3 1/4 3/4 Good (n = 3) CY good in 1/2 patients (62)
Anti-CNTN1
Querol et al. (2013) 3/3 2/3, only partial – – CY no (n = 1), AZA partial (n = 1) (45)
Querol et al. (2015) – – – Good (n = 1) – (75)
Miura et al. (2015) 8/11 4/10 – CY no (n = 2) (56)
Doppler et al. (2015a) - 3/3 only at initial phase 1/1, only partial Good (n = 1) CY good (n = 1) (54)
Anti-Caspr
Doppler et al. (2016) 1/1, partial 0/1 1/1 Good (n = 1) – (46)
Anti-NF186/140
Delmont et al. (2017) 3/5 3/4 1/2 Good (n = 1) CY good (n = 1) (47)
Burnor et al. (2018) – 1/1 (temporary) 1/1 (temporary) Good (n = 1) CY favorable (n = 1) (62)
IVIG, intravenous immunoglobulin; PE, plasma exchange; RTX, rituximab; CY, cyclophosphamide; MMF, mycophenolate mofetil; AZA, azathioprine.
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The significant differences in the clinical management of sero-
positive and seronegative CIDP patients from disease onset make 
autoantibody-testing in CIDP patients a necessity regardless of 
the rarity (~10%) of these antibodies.
TReATMeNT iMPLiCATiONS
An important implication of testing antibody positivity in 
CIDP patients is the selection of the most suitable treatment 
approach for the individual patient. There are no prospective 
clinical trials yet; however, retrospective observations provided 
some insight regarding the treatment response (Table 7). IVIG 
treatment is not satisfactory in the majority of seropositive 
CIDP patients, especially in patients with anti-NF155 antibo-
dies. In the study by Kadoya et al., 3/11 of the anti-NF-155 IgG 
patients responded to IVIG, whereas this ratio was 42/46 in the 
seronegative group (58). Similarly, the ratio of the patients with 
positive response to IVIG was less than 40% in other studies 
(28, 50, 52, 62). For patients with anti-CNTN1 antibodies, 
Miura et  al. reported that 4/10 of the patients had a positive 
response to IVIG (56) and in two other studies, patients 
benefited from IVIG in the initial phase of the disease but only 
temporarily (45, 54). Similarly, one anti-Caspr IgG positive 
patient did not respond to IVIG. Poor response to IVIG may 
be explained by the lack of complement fixing capacity of the 
IgG4 subtype (71). Among patients with a poor response to 
IVIG, 6/8 patients responded favorably to corticosteroids or 
plasma exchange (58). Similarly, response to steroids or plasma 
exchange was more favorable in IVIG-resistant patients in 
other studies (28, 45, 52, 56, 62). In one study, four seropositive 
CIDP patients with resistance to corticosteroids and IVIG were 
treated with RTX (75). In all patients, antibody levels declined 
following treatment and three patients responded to therapy. 
In two of these patients, disease duration was less than 1 year 
and the treatment response was robust in these patients com-
pared to the third patient with a long disease duration and 
limited RTX response (75). In another study, all three patients 
with anti-NF155 antibodies had a prominent response to RTX 
(62). Of note, one of these patients recovered from a locked-in 
state after RTX and cyclophosphamide. Additional singlet cases 
with seropositive CIDP and a robust response to RTX were also 
reported (46, 54). In a separate case with a devastating form of 
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anti-NF155 antibody positive CIDP, who was resistant to all 
levels of treatments, autologous stem cell transplantation was 
tried and found to be very effective (92).
Furthermore, studies suggest that it is especially important to 
implement a rapid and effective maintenance therapy regimen 
in seropositive patients after management of the initial relapse 
to prevent irreversible axonal degeneration. In the absence of 
maintenance therapy, progressive clinical decline is seen and 
irreversible axonal damage may pursue. Data on which therapies 
are effective for maintenance is scarce.
UNANSweReD QUeSTiONS
 – Are any other yet unidentified autoantibodies implicated in 
CIDP or CCPD?
 – High CSF protein and gadolinium enhancement of the nerve 
roots and plexuses indicate inflammation in proximal nerves 
which was not seen in sural nerve biopsies. What is the 
mechanism behind this?
 – Why is seropositive-CIDP almost always associated with 
the IgG4 subtype whereas GBS patients have IgG1 or IgG3 
subtype?
 – How do subtle paranodal changes lead to severe axonal 
degeneration?
 – What is the mechanism of tremor that is seen in patients 
with anti-NF155 antibodies? Do these antibodies pass to the 
CSF?
 – Is nodopathy with or without the involvement of antibodies 
an important disease mechanism in CNS disorders?
 – T  cell response to nodal antigens in seropositive patients 
largely unexplored
CONCLUSiON
Discovery of the autoantibodies like anti-Aqp4 and anti-MOG in a 
fraction of patients with central demyelinating disorders changed 
our understanding and treatment of these disorders. Likewise, dis-
covery of anti-neuronal antibodies in numerous CNS syndromes, 
recognition of their value as a biomarker and studies on the effect 
of these antibodies on CNS-pathology has dramatically contrib-
uted to the field of clinical neuroimmuno logy. Discovery of the 
autoantibodies against nodal antigens in some patients with CIDP 
has a potential to have a similar effect on the field of inflammatory 
neuropathies. Additional studies are necessary to elucidate the full 
spectrum of autoantibodies and their clinical characteristics.
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